Company News
Piper Sandler Upgrades Biogen Overweight
Piper Sandler raised Biogen's price target to $214 from $177 and upgraded rating to Overweight, citing acquisition strength.
The Apellis assets add Empaveli and Syfovre, offsetting MS drug revenue dec
